Recursion Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham reiterated a Buy rating on the stock and has a $8.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gil Blum has given his Buy rating due to a combination of factors related to the promising results from Recursion Pharmaceuticals’ ongoing clinical study. The updated data from the Phase Ib/2 TUPELO study of REC-4881 in patients with Familial Adenomatous Polyposis (FAP) showed that 75% of evaluable patients experienced a reduction in polyps from baseline. This positive outcome suggests a significant drug effect, which is a strong indicator of the potential success of REC-4881.
Additionally, the durability of the treatment effect observed at 25 weeks, even after stopping the dosing at week 12, adds to the confidence in the drug’s efficacy. Although typical toxicities associated with MEK inhibitors were noted, these are expected to be manageable with appropriate mitigation strategies in future studies. The promising results and the planned meeting with the FDA in the first half of 2026 further support the Buy rating, as they indicate a clear path forward for the development and potential approval of REC-4881.
According to TipRanks, Blum is a 4-star analyst with an average return of 7.1% and a 39.12% success rate. Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Nurix Therapeutics, and Rocket Pharmaceuticals.